Zhengye Biotechnology Holding (ZYBT) Common Equity (2023 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Common Equity of $43.2 million for Q4 2025, down 11.89% year-over-year from $49.1 million in Q4 2024, and up 3.63% quarter-over-quarter from $41.7 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Common Equity (2023 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Common Equity for 3 consecutive years, with $43.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 11.89% year-over-year to $43.2 million; the TTM figure through Dec 2025 stood at $43.2 million (down 11.89% YoY), while the FY2025 annual figure was $43.9 million, down 9.21% from the prior year.
- Common Equity advanced to $43.2 million in Q4 2025 per ZYBT's latest filing, from $41.7 million in the prior quarter.
- Across five years, Common Equity topped out at $49.1 million in Q4 2024 and bottomed at $41.7 million in Q2 2025.
- Historically, Common Equity has averaged $45.3 million across 3 years, with a median of $45.2 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity increased 4.16% — and 2025, when it declined 11.89%.
- Zhengye Biotechnology Holding's Common Equity stood at $47.1 million in 2023, then climbed by 4.16% to $49.1 million in 2024, then slipped by 11.89% to $43.2 million in 2025.
- Business Quant data shows ZYBT's Common Equity at $43.2 million in Q4 2025, $41.7 million in Q2 2025, and $49.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Zhengye Biotechnology Holding | 88.07 Mn | 80.75 Mn | - | 43.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43.24 Mn |
| Jun 30, 2025 | 41.73 Mn |
| Dec 31, 2024 | 49.08 Mn |
| Dec 31, 2023 | 47.12 Mn |